Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2025 May 30;44(1):165.
doi: 10.1186/s13046-025-03426-3.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Lorenzo Castagnoli  1 , Alma Franceschini  1 , Valeria Cancila  2 , Matteo Dugo  3 , Martina Bigliardi  1 , Claudia Chiodoni  4 , Paolo Toneguzzo  1 , Viola Regondi  1 , Paola A Corsetto  5 , Filippo Pietrantonio  6 , Serena Mazzucchelli  7 , Fabio Corsi  8 , Antonino Belfiore  9 , Andrea Vingiani  9   10 , Giancarlo Pruneri  9   10 , Francesca Ligorio  6   11 , Mario P Colombo  4 , Elda Tagliabue  1 , Claudio Tripodo  2   11 , Claudio Vernieri  6   11 , Tiziana Triulzi  1 , Serenella M Pupa  12
Affiliations
Published Erratum

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Lorenzo Castagnoli et al. J Exp Clin Cancer Res. .
No abstract available

PubMed Disclaimer

Erratum for

  • CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
    Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, Toneguzzo P, Regondi V, Corsetto PA, Pietrantonio F, Mazzucchelli S, Corsi F, Belfiore A, Vingiani A, Pruneri G, Ligorio F, Colombo MP, Tagliabue E, Tripodo C, Vernieri C, Triulzi T, Pupa SM. Castagnoli L, et al. J Exp Clin Cancer Res. 2025 Jan 20;44(1):19. doi: 10.1186/s13046-025-03276-z. J Exp Clin Cancer Res. 2025. PMID: 39833955 Free PMC article.

References

    1. Castagnoli L, Franceschini A, Cancila V, et al. CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. J Exp Clin Cancer Res. 2025;44:19. 10.1186/s13046-025-03276-z. - PMC - PubMed

Publication types

LinkOut - more resources